Enhancing Clinical Diagnosis for Patients With Persistent Pulmonary Abnormalities After COVID-19 Infection: The Potential Benefit of 68 Ga-FAPI PET/CT

Anna Sviridenko,Anna Boehm,Gianpaolo di Santo,Christian Uprimny,Bernhard Nilica,Josef Fritz,Frederik L Giesel,Uwe Haberkorn,Sabina Sahanic,Clemens Decristoforo,Ivan Tancevski,Gerlig Widmann,Judith Loeffler-Ragg,Irene Virgolini
DOI: https://doi.org/10.1097/RLU.0000000000004437
2022-12-01
Abstract:Patients and methods: Six post COVID-19 patients suspected for pulmonary fibrosis were scheduled for dual-tracer PET/CT with 18 F-FDG and 68 Ga-fibroblast activation protein inhibitor (FAPI)-46. The uptake of 68 Ga-FAPI-46 in the involved lung was compared with a control group of 9 non-COVID-19 patients. Clinical data and PET/CT imaging were collected and analyzed. Results: PET/CT revealed in all 6 pulmonary impaired patients the reduced glucose avidity on 18 F-FDG and clear positivity on 68 Ga-FAPI-46 PET/CT in comparison to the control group. Conclusions: Enhancing fibrotic repair mechanisms, 68 Ga-FAPI PET/CT may improve noninvasive clinical diagnostic performance in patients with long-term CT abnormalities after severe COVID-19. Although this study shows promising results, additional studies in larger populations are required to establish a general diagnostic guideline.
What problem does this paper attempt to address?